Erenumab-Aooe
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Trigeminal Neuropathy
Conditions
Trigeminal Neuropathy
Trial Timeline
May 31, 2022 → Oct 27, 2022
NCT ID
NCT05142228About Erenumab-Aooe
Erenumab-Aooe is a phase 2 stage product being developed by Amgen for Trigeminal Neuropathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT05142228. Target conditions include Trigeminal Neuropathy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05142228 | Phase 2 | Terminated |
| NCT06150781 | Pre-clinical | Recruiting |
Competing Products
7 competing products in Trigeminal Neuropathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab | Eli Lilly | Approved | 85 |
| Rimegepant + Placebo | Pfizer | Phase 2 | 51 |
| BIIB074 Treatment A + BIIB074 Treatment B + BIIB074 Treatment C + BIIB074 Treatment D | Biogen | Phase 1 | 30 |
| CNV1014802 + Placebo | Biogen | Phase 1 | 30 |
| CNV1014802 + Placebo | Biogen | Phase 2 | 49 |
| BIIB074 + Placebo | Biogen | Phase 3 | 74 |
| BIIB074 + Placebo | Biogen | Phase 3 | 74 |